Vera Therapeutics/$VERA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Ticker
$VERA
Sector
Primary listing
Employees
192
Headquarters
Website
VERA Metrics
BasicAdvanced
$1.6B
-
-$3.59
1.17
-
Price and volume
Market cap
$1.6B
Beta
1.17
52-week high
$49.23
52-week low
$18.53
Average daily volume
1.7M
Financial strength
Current ratio
17.028
Quick ratio
16.72
Long term debt to equity
16.379
Total debt to equity
16.561
Interest coverage (TTM)
-31.58%
Profitability
EBITDA (TTM)
-235.767
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-30.24%
Return on equity (TTM)
-54.83%
Valuation
Price to book
3.37
Price to tangible book (TTM)
3.37
Price to free cash flow (TTM)
-8.062
Free cash flow yield (TTM)
-12.40%
Free cash flow per share (TTM)
-3.07
Growth
Earnings per share change (TTM)
62.00%
3-year earnings per share growth (CAGR)
14.44%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Bulls say / Bears say
Robust cash runway: As of December 31, 2024, Vera reported $640.9 million in cash, equivalents, and marketable securities, which management believes is enough to fund operations through potential approval and a 2026 U.S. launch of atacicept (GLOBE NEWSWIRE)
Full enrollment achieved: Vera completed full enrollment of 431 participants in the pivotal ORIGIN Phase 3 trial for atacicept in IgAN, positioning it to report the 36-week primary endpoint in Q2 2025 and move forward with regulatory submission plans (Globe Newswire)
Clear regulatory path: Vera is on track to submit a BLA for accelerated approval of atacicept in H2 2025 following its pivotal ORIGIN trial, with the chance to become the first dual BAFF/APRIL inhibitor approved for IgAN (GLOBE NEWSWIRE)
Intensifying competition: Otsuka’s APRIL inhibitor sibeprenlimab has secured FDA priority review with a PDUFA date of November 28, 2025, potentially gaining first-mover advantage ahead of Vera’s atacicept application (Otsuka)
Shrinking cash reserves: Vera’s cash, cash equivalents and marketable securities dropped from $640.9 million at December 31, 2024 to $556.8 million as of June 30, 2025, highlighting funding risk if clinical or regulatory delays extend its burn rate (SEC 10-Q)
Regulatory timeline risk: Atacicept’s BLA submission depends on positive Phase 3 ORIGIN data expected in Q2 2025, with filing targeted for H2 2025 and no guarantee of accelerated approval, prolonging the pre-commercial risk window (GLOBE NEWSWIRE)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
VERA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vera Therapeutics stock?
Vera Therapeutics (VERA) has a market cap of $1.6B as of September 10, 2025.
What is the P/E ratio for Vera Therapeutics stock?
The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of September 10, 2025.
Does Vera Therapeutics stock pay dividends?
No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of September 10, 2025.
When is the next Vera Therapeutics dividend payment date?
Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vera Therapeutics?
Vera Therapeutics (VERA) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.